C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy…

Related Keywords

,Data Support ,Optimal Dosing Schedule ,Well Tolerated ,Promising Signs ,Immunomodulatory Effects ,Novel Multiple Myeloma Agents ,News ,Ggregator ,Reaking News ,Uration ,Media ,